In the future, medical institutions

[Mst.Rina1R]

That have been reviewed by the Ministry of Health and Welfare and have doctors, pharmacists and nursing staff specialized in regenerative medicine can perform such treatments, and records must be provided regularly; pharmaceutical companies must also be reviewed and pass the second phase of clinical trials. Conditionally marketed, refer to the US system, and observe clinical data while selling.

Moreover, this may be an opportunity for Taiwan's biotech industry to compete with the international community.

An anonymous medical expert who runs one of Taiwan's top five medical centers pointed out that "Taiwan has a niche in cell therapy." He explained that compared with fields such as small molecule drugs and hong kong telegram vaccines, which have been developed for more than a hundred years, cell therapy has been around for nearly 20 years. In an emerging field that has only emerged in recent years, "this regulation has helped the biotechnology industry a lot." This has also prompted many hospitals to actively integrate with the industry, cooperate in the development of new drugs, and assist in clinical treatment.

Not only do biotechnology companies have the opportunity to earn income through new drug research and development and the exclusive 20-year patent period of new drugs, but it also benefits patients.

Wu Shang-ru, a hematology oncologist at National Taiwan University Hospital, pointed out that when the industry wants to advance laboratory research and development to the market stage, it will inevitably have to conduct a large number of clinical trials in Taiwan. In this way, this group of terminal cancer patients who are racing against time will have the opportunity to participate in clinical trials and receive treatment earlier before new drugs are launched.